Pharma M&A: 10 years, 1,345 deals, $694B

It's been a busy decade for pharma dealmaking. During the 10 years that ended Dec. 31, 2009, a total of 1,345 mergers and acquisitions of pharmaceutical assets and companies were announced, with disclosed prices totaling more than $694 billion, according to

The biggest deal: GlaxoWellcome's $74 billion merger with SmithKline Beecham in 2000 that created GlaxoSmithKline. That year, pharma did more than $97 billion worth of deals.

But the biggest dealmaking year of all--to no one's surprise--was last year. In 2009, drugmakers' deals amounted to $147.2 billion, Levin Associates calculates. That, of course, includes Pfizer's $68 billion deal for Wyeth and Merck's $41 billion deal with Schering-Plough.

The deals encompass generics buyouts--Teva Pharmaceutical Industries' $8.96 billion buyout of Barr Pharmaceuticals and $7.96 billion deal for Ivax, for instance. Then there's consumer healthcare: Johnson & Johnson bought Pfizer's consumer unit in 2006 for $16.6 billion. And there are those megadeals that created the Big Pharma we know today: That GSK merger above, for instance, or Sanofi-Synthelabo's $65.6 billion acquisition of Aventis in 2004. Or Bayer's $21.5 billion deal for Schering in 2006. We could go on and on.

- read the release from Irving Levin

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.